undamentalytics Newsletter
Sign in

Vyome Holdings, Inc income statement

In fiscal 2025, Vyome Holdings, Inc reported revenue of $319,714, down 96.0% on the year before, operating income of −$10.5m (a -3269.4% margin) and net income of −$10.3m, or −$4.86 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue44310931114119800
Cost of revenue3335535543000
Gross profit1215406876000
Research and development61310111173232012
Selling, general and administrative531029301759148123
Operating income−10−15−20−34−37−23−12−58−46−15−1−10−12
Interest expense——————————000
Income before tax——————−22−63−47−11−7——
Income tax0−00000−0−0−000——
Net income−10−16−20−35−37−24−22−63−46−11−1−10−11
Diluted EPS−$4652.50−$6785.00−$1212.50−$208.00−$1964.00−$503.00−$555.00−$577.94−$435.60−$110.87−$6001.39−$4.86—
Diluted shares (average)————19m——————2m—
EBITDA−10−15−19−34—−23−12−58−46−15−1−10−12

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AKAN vs HINDHIND vs SCNXHIND vs PRFX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Vyome Holdings, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vyome Holdings, Inc.